#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3750	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2552	436.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1984	1984	T	485	T,A,G	409,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3750	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2552	436.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1718	1718	C	628	C,T	498,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3750	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2552	436.5	0	HET	.	.	.	A69G,C	.	69	69	A	603	603	A	537	A,G,C	220,240,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6190	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4084	453.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1969	1969	A	524	A	435	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6190	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4084	453.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2603	2603	C	599	C,T,A	481,3,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6190	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4084	453.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2677	2677	A	601	A,C	487,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6190	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4084	453.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3229	3229	C	530	C	418	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	628	folP	852	852	99.88	folP.l6.c17.ctg.1	1835	102.2	0	.	p	.	0	E151K	NONSYN	451	453	GAA	943	945	AAA	130;128;128	A;A,C;A	110;106,1;110	.	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	628	folP	852	852	99.88	folP.l6.c17.ctg.1	1835	102.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1174	1176	AGC	149;149;149	A;G;C	120;118;117	folP.WHO_N_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1162	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3665	94.9	1	SNP	p	S91F	0	.	.	271	273	TCC	696	698	TCC	98;98;98	T;C;C,G	76;81;81,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1162	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3665	94.9	1	SNP	p	D95G	0	.	.	283	285	GAC	708	710	GAC	94;94;94	G;A;C	79;78;80	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1162	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3665	94.9	1	SNP	p	D95N	0	.	.	283	285	GAC	708	710	GAC	94;94;94	G;A;C	79;78;80	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	552	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1857	89.1	1	SNP	p	G45D	0	.	.	133	135	GGC	740	742	GGC	151;151;152	G;G;C	125;124;126	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	288	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1301	66.0	0	.	n	.	0	A197.	DEL	197	197	A	759	759	A	132	A	105	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1264	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3348	112.8	1	SNP	p	D86N	0	.	.	256	258	GAC	737	739	GAC	141;139;140	G;A;C	105;109;111	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1264	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3348	112.8	1	SNP	p	S87R	0	.	.	259	261	AGT	740	742	AGT	138;140;140	A;G;T	104;114;107	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1264	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3348	112.8	1	SNP	p	S87I	0	.	.	259	261	AGT	740	742	AGT	138;140;140	A;G;T	104;114;107	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1264	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3348	112.8	1	SNP	p	S87W	0	.	.	259	261	AGT	740	742	AGT	138;140;140	A;G;T	104;114;107	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1264	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3348	112.8	1	SNP	p	S88P	0	.	.	262	264	TCC	743	745	TCC	140;143;142	T,G,A;C,A;C,G,A	105,1,1;105,1;110,1,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1124	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3055	110.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1726	1728	GGC	180;180;180	G;G,A;C	137;143,1;138	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1458	1460	GCA	162;162;162	G;C,A;A,C	124;126,1;121,2	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1461	1463	ATC	163;163;162	A,T;T;C,A	126,1;122;124,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1473	1475	GTG	159;159;159	G,C;T,G;G,A	126,1;120,1;122,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1473	1475	GTG	159;159;159	G,C;T,G;G,A	126,1;120,1;122,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1977	1979	ACC	120;121;122	A;C;C	91;95;97	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2031	2033	GCG	113;112;112	G;C;G	91;79;81	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2031	2033	GCG	113;112;112	G;C;G	91;79;81	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2154	2156	GGC	124;124;124	G,C;G;C	97,1;98;98	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2163	2165	GGC	128;126;125	G,T;G,T;C	91,1;96,1;96	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1006	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2953	101.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2181	2183	CTG	121;121;122	C;T,G;G	96;97,1;100	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1308	ponA	2397	2397	100.0	ponA.l6.c17.ctg.1	3572	109.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1941	1943	CCG	119;119;119	C;C;G	94;95;93	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	632	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2269	83.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	762	762	C	86	C,G	69,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1025	1027	AAT	17;17;17	A;A;T	14;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1028	1030	AAT	17;17;17	A;A;T	14;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1052	1054	GCA	16;16;16	G;C;A	14;13;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1075	1077	GTA	16;16;15	G;T;A	14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	S236N	NONSYN	706	708	AGC	1081	1083	AAC	15;15;15	A;A;C	14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	.	MULTIPLE	709	711	AAC	1085	1089	TGGCG	15;15;15;15;15	T;G;G;C;G	14;14;14;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	D238A	NONSYN	712	714	GAT	1091	1093	GCT	15;15;15	G;C;T	13;14;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1151	1153	TTA	16;16;16	T;T;A	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1196	1198	CAT	16;16;16	C;A;T	12;11;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1199	1201	AGT	16;16;16	A;G;T	12;12;12	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	297	90.37	porB1a.l6.c30.ctg.1	1297	19.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1208	1210	TAC	16;16;16	T;A;C	12;12;12	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	866	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2188	118.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	682	684	GAA	155;155;155	G;A;A	119;123;127	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	866	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2188	118.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	970	972	GAT	205;205;206	G;A;T,G	160;156;152,2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	866	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2188	118.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1093	1095	TCA	196;197;197	T,A,C;C;A	153,1,1;164;162	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	866	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2188	118.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1222	1224	GTC	185;182;183	G;T,G;C	148;151,1;149	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	866	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2188	118.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1552	1554	GCA	198;199;196	G,T;C,A;A,C	156,3;159,1;144,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	866	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2188	118.4	1	SNP	p	G120K	1	.	.	358	360	AAG	928	930	AAG	205;204;204	A;A;G	160;159;156	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	866	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2188	118.4	1	SNP	p	A121D	1	.	.	361	363	GAC	931	933	GAC	205;207;208	G;A;C,A	160;161;162,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	866	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	2188	118.4	1	SNP	p	D121N	0	.	.	361	363	GAC	931	933	GAC	205;207;208	G;A;C,A	160;161;162,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2794	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5159	162.2	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2165	2167	AAT	144;145;145	A;A;T	112;115;113	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	444	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1337	98.8	1	SNP	p	V57M	1	.	.	169	171	ATG	629	631	ATG	196;195;195	A;T;G	155;154;160	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
